The Selling of Attention Deficit Disorder
Alan Schwarz (New York Times)
Orphan Drug Designations: Why You Should Care
Jason Napodano, Jolene Lau and John Tucker (Zachs / SeekingAlpha)
Grab your favorite hot beverage - this is a thorough (long) read about ODD and goes way beyond whether one should obsess over short term trading in response to ODD announcements
What Was Hyped, and What Fell Out of Favor, This Year in Biotech
Luke Timmerman (Xconomy)
Pfizer's R&D Chief On How Drug Research Is Evolving
Matthew Herper (Forbes)
Crowdfunding: Angels in Biotech, or Devil in the Details? [and]
Introducing Atlas’ Biotech Seed Class of 2013
Bruce Booth (LifeSciVC)
A two-for-one this week with some nice insights about forming, nurturing, and growing a successful company - or pulling the plug when things don't go as well
The future of pharma sales reps
Frank David (Pharmagellan)
Will GSK's Sales And Marketing Changes Result In Lower Revenues?
John LaMattina (Forbes)
Two takes on the announcements made by GSK about not paying doctors to promote their medicines and not pay sales reps based on prescription volume
Skip the Supplements
Paul Offit and Erush (CHOP / New York TImes)
I passed on the second-hand smoking and vaccine stories this week in favor of this one as my "scold of the week" choice
Alan Schwarz (New York Times)
Orphan Drug Designations: Why You Should Care
Jason Napodano, Jolene Lau and John Tucker (Zachs / SeekingAlpha)
Grab your favorite hot beverage - this is a thorough (long) read about ODD and goes way beyond whether one should obsess over short term trading in response to ODD announcements
What Was Hyped, and What Fell Out of Favor, This Year in Biotech
Luke Timmerman (Xconomy)
Pfizer's R&D Chief On How Drug Research Is Evolving
Matthew Herper (Forbes)
Crowdfunding: Angels in Biotech, or Devil in the Details? [and]
Introducing Atlas’ Biotech Seed Class of 2013
Bruce Booth (LifeSciVC)
A two-for-one this week with some nice insights about forming, nurturing, and growing a successful company - or pulling the plug when things don't go as well
The future of pharma sales reps
Frank David (Pharmagellan)
Will GSK's Sales And Marketing Changes Result In Lower Revenues?
John LaMattina (Forbes)
Two takes on the announcements made by GSK about not paying doctors to promote their medicines and not pay sales reps based on prescription volume
Skip the Supplements
Paul Offit and Erush (CHOP / New York TImes)
I passed on the second-hand smoking and vaccine stories this week in favor of this one as my "scold of the week" choice
RSS Feed
